补肾衍精汤联合左卡尼汀治疗少弱精症的临床观察

目的:观察中药补肾衍精汤联合左卡尼汀口服液治疗少弱精症的临床疗效。方法:选取符合标准的68例少弱精症患者给予补肾衍精汤配合左卡尼汀口服液内服。结果:68例患者治疗后痊愈21例,显效26例,有效11例,无效6例,脱落4例,总有效率为85.29%。与治疗前相比,治疗3个月后患者的精液量、精子密度、精子活动率、精子活力均有显著变化,其差异均有统计学意义(均P0.05)。结论:补肾衍精汤联合左卡尼汀口服液可以明显改善少弱精症患者的精液质量,提高临床疗效。     

左卡尼汀联合黄精赞育胶囊治疗雷达作业人员少弱精症的临床观察

目的:本文旨在探讨应用左卡尼汀联合黄精赞育胶囊治疗雷达作业人员少弱精症的临床疗效。方法:选取60名服役2年以上的雷达作业官兵,随机分为治疗组和对照组,每组各30例。治疗组采用左卡尼汀联合黄精赞育胶囊治疗,对照组单纯采用黄精赞育胶囊治疗。分别对治疗前和治疗后3个月的精液参数进行分析。结果:治疗组的总有效率为86.7%,对照组的总有效率为60%,两组差异具有统计学意义(P0.05)。治疗组和对照组在治疗后精子密度、精子活力均较治疗前明显改善,差异具有统计学意义(P0.05);治疗组治疗后和对照组治疗后比较,精子密度没有显著差异(P0.05);但是精子活力治疗组显著高于对照组,差异具有统计学意义(P0.05)。结论:左卡尼汀联合黄精赞育胶囊治疗雷达作业人员少弱精症临床疗效显著。     

苁蓉益肾颗粒联合左卡尼汀治疗少弱精子症的临床观察

目的:观察苁蓉益肾颗粒联合左卡尼汀治疗少弱精症的临床疗效及对精子参数水平的影响。方法:将400例本病患者随机分为治疗组与对照组各200例,对照组采用左卡尼汀治疗,治疗组服苁蓉益肾颗粒和左卡尼汀治疗,疗程3个月。观察临床疗效和治疗前后精液各参数(精子密度、活动率、活力)的变化。结果:治疗组总有效率为92.00%,显著高于对照组的65.00%(P0.01);两组治疗前各精液指标比较,差异均无统计学意义(P0.05);两组治疗后各精液指标均较治疗前显著改善(P0.01),且治疗组治疗后精子计数、精子成活率、a级及a+b级指标依次为(33.1±13.4)×10~6/mL、(67.9±19.8)%、(24.7±5.9)%、(52.6±17.9)%,改善程度均更优于对照组(P0.05)。结论:苁蓉益肾颗粒联合左卡尼汀可明显改善少弱精子症不育患者的精液质量,提高临床疗效。     

“化浊育精颗粒”治疗精子DNA损伤男性不育患者临床观察

目的观察"化浊育精颗粒"治疗精子DNA损伤男性不育患者的作用。方法选择120例合并有精子DNA完整性异常的男性不育患者,将其随机分为治疗组和对照组,每组60例患者。治疗组患者口服"化浊育精颗粒",对照组患者口服左卡尼汀口服液,治疗周期均为3个月。治疗前和治疗后,采用计算机辅助精子分析系统与流式细胞仪分别检测两组患者精液常规参数和精子DNA碎片化指数(DNA fragmentation index,DFI)。结果治疗前,两组患者DFI差异无统计学意义(P0.05);治疗前后,两组患者精子DFI改善比较,其差异均具有统计学意义(均P0.05);治疗后,治疗组患者精子DFI均值(19.5±2.2)低于对照组患者(24.2±4.3),其差异具有统计学意义(P0.05);两组患者对精子DFI疗效差异具有统计学意义(P0.05)。结论对于精子DNA损伤男性不育,"化浊育精颗粒"和左卡尼汀口服液均可以降低精子DFI,但"化浊育精颗粒"对减轻精子DNA损伤具有更好的疗效。     

五子衍宗软胶囊联合左卡尼丁口服液治疗男性弱精症的临床研究

目的:探讨五子衍宗软胶囊联合左卡尼丁口服液治疗男性弱精症临床效果,以期提高疗效。方法:选取2011年6月至2013年6月116例男性弱精症患者为研究对象,分成两组,对照组58例,使用左卡尼丁口服液治疗,观察组58例,加用五子衍宗软胶囊,观察治疗后在精液质量和血清指标变化情况。结果:对照组治愈率15.52%、总有效率67.24%,观察组治愈率25.86%、总有效率84.48%,两组比较差异显著(P0.05);两组治疗后在精液量、精子密度、精子活率、a级精子、(a+b)级精子活力上较治疗前均显著提高,治疗前后比较差异显著(P0.05),观察组治疗后在精液量、精子密度、精子活率、a级精子、(a+b)级精子活力较对照组治疗后提高更加显著,两组治疗后比较差异显著(P0.05);两组治疗后睾酮含量较治疗前均显著提高,治疗前后比较差异显著(P0.05),而两组在FSH、LH、P、PRL上治疗前后均无显著差异(P0.05)。结论:五子衍宗软胶囊联合左卡尼丁口服液治疗男性弱精症有协同作用,能提高疗效。     

五子衍宗丸联合复方玄驹胶囊治疗少弱精症患者30例疗效观察

目的:观察五子衍宗丸联合复方玄驹胶囊治疗少弱精症患者的临床疗效。方法:将86例少弱精症患者随机分成联合治疗组30例、五子衍宗组28例和复方玄驹组28例,五子衍宗组和复方玄驹组分别给予五子衍宗丸和复方玄驹胶囊治疗。联合治疗组予以五子衍宗丸联合复方玄驹胶囊口服治疗,治疗3个月后观察临床疗效,并检测治疗前后三组患者精液常规指标、精子运动轨迹的变化。结果:联合治疗组、复方玄驹组和五子衍宗丸组的临床疗效总有效率分别为83.33%、67.86%和60.71%,差异具有统计学意义(P0.05)。三组治疗后精子密度、精子活动率、a级精子比例、(a+b)级精子比例水平与治疗前比较,差异均有统计学意义(P0.05)。联合治疗组治疗后各指标水平与其他两组同时间比较,差异均有统计学意义(P0.05)。结论:五子衍宗丸联合复方玄驹胶囊口服治疗能明显改善少弱精症患者的精液治疗指标。     

复方玄驹胶囊与它莫西酚锌制剂综合治疗少弱精症临床效果观察

目的:探讨复方玄驹胶囊与它莫西酚锌制剂联合治疗少弱精症的临床疗效,为治疗该病提供参考依据。方法:收集日照市妇幼保健院2014年1月至2016年12月间收治的240例少弱精症患者作为研究对象,按照随机数字表法分为研究组与对照组,对照组给予复方玄驹胶囊治疗,而研究组给予复方玄驹胶囊与它莫西酚锌制剂联合治疗,对两组患者的临床治疗效果进行观察。结果:研究组患者临床治疗总有效率86.67%,显著优于对照组的68.33%,组间数据差异具有统计学意义(P0.05);治疗后研究组患者精子密度、精子活力、精液量和精子活动率均较治疗前有明显的改善,且优于对照组,组间数据差异具有统计学意义(P0.05)。结论:临床中对于少弱精症患者给予复方玄驹胶囊与它莫西酚锌制剂综合的临床疗效显著,改善患者精子密度与活力,值得临床中应用与推广。     

麒麟丸联合左卡尼汀治疗少弱精子症疗效观察

目的:探讨麒麟丸联合左卡尼汀对少弱精子症的疗效。方法:将120例男性少弱精子症患者随机分为3组,A组为联合用药治疗组,B组为左卡尼汀治疗组,C组为麒麟丸治疗组,治疗前、后2个月对病例进行精液参数分析。结果:与治疗前相比,A、C组患者治疗后精子密度及活力提高(P0.01),但C组精子活力的改善明显低于A组;B组治疗后精子活力提高,密度无明显变化。结论:左卡尼汀联合麒麟丸可提高患者的精子密度和活力。     

二仙补肾益精解毒方改善无症状性弱精子症患者精子活力临床研究

目的:评价二仙补肾益精解毒方改善无症状性弱精子症患者精子活力的临床疗效和安全性。方法:将72例无症状性弱精子症患者按随机对照的试验方法分成试验组和对照组,试验组用二仙补肾益精解毒方免煎颗粒每日1剂、早晚各半剂进行治疗,对照组用左卡尼汀口服液每次1支、每日2次进行治疗,疗程11周。整个疗程中治疗不中断,采用治疗前、治疗后对照研究的方法客观评价二仙补肾益精解毒方对无症状性弱精子症患者的疗效。重点观察无症状性弱精子症患者精液精子总活力(PR+NP)、前向运动精子百分率(PR)变化,同时注意对药物毒副作用的观察。结果:试验组精子总活力、前向运动精子百分率治疗前后比较采用配对t检验,差异均有显著统计学意义(P0.01);对照组精子总活力、前向运动精子百分率治疗前后比较采用配对t检验,精子总活力的差异无统计学意义(P0.05),前向运动精子百分率的差异有统计学意义(P0.05);两组治疗后精子总活力、前向运动精子百分率,两组比较采用成组t检验,差异均有统计学意义(P0.05);治疗前后精子总活力差值及前向运动精子百分率差值,两组比较采用成组t检验,其中精子总活力差值的差异均有统计学意义(P0.05),前向运动精子百分率差值的差异具有显著统计学意义(P0.01)。试验组显效、有效、无效例数分别为17、10、3例;对照组显效、有效、无效例数分别为10、9、10例。两组精子活力总体疗效比较采用Mann-Whitney U检验,差异具有统计学意义(P0.05)。除对照组1例患者药物过敏,试验组1例患者失访外,两组患者在治疗过程中均未出现头晕、头痛、腹痛、腹泻、恶心、呕吐等明显的局部和全身不良反应。结论:采用二仙补肾益精解毒方治疗无症状性弱精子症安全有效。     

小剂量氯米芬与左卡尼汀联合治疗特发性少弱精症

目的:探讨小剂量氯米芬联合左卡尼汀治疗特发性少弱精子症的疗效和安全性。方法:根据WTO标准选择特发性少弱精子症患者60例,给予小剂量氯米芬(25mg),每日1次;左卡尼汀口服液1.0g,每日2次。两种药物连服3个月为1疗程,根据情况,维持治疗1～2个疗程。分别于治疗前、治疗后3个月及6个月行计算机辅助精液分析。治疗开始后2周、4周及3个月,用放射免疫法测定血清睾酮(T)卵泡刺激素(FSH)。治疗中分别有8例患者和5例患者的血清睾酮水平和FSH水平超出正常值高限,随即减低氯米芬剂量至25mg,隔日1次。治疗中了解配偶妊娠情况及不良反应发生情况。结果:随访3～6个月,有10例患者因各种原因(2例女方妊娠)提前退出。服药后,患者的睾酮及卵泡刺激素迅速升高,接近正常上限水平。治疗后患者的精子密度及前向运动精子百分率较治疗前增加显著(P<0.05),治疗后女方妊娠者为11例。治疗期间,所有患者均未报告明显的不良反应。结论:小剂量氯米芬联合左卡尼汀治疗特发性少弱精子症能有效提高患者精子密度及前向运动精子百分率,增加妊娠率,无明显不良反应。     

New fillers for the new man

ABSTRACT:  Two new collagen-based lidocaine-containing dermal fillers, ArteSense™/ArteFill™ (Artes Medical, San Diego, CA) and Evolence® (Colbar LifeScience Ltd., Herzliya, Israel), have proved to be of particular interest to men, many of whom seek a long-lasting or permanent correction. ArteFill™ has been available in the United States since 2006, and it is expected that Evolence® will reach the American market in 2008. The properties of the two products will be described, and experience based on the administration of many hundreds of syringes of both products by a Canadian dermatologist will be detailed here, with tips and precautions to optimize patient outcomes.     

Outcomes and adverse effects of ablative vs nonablative lasers for skin resurfacing: A systematic review of 1093 patients

It is generally believed that ablative laser therapies result in prolonged healing and greater adverse events when compared with nonablative lasers for skin resurfacing. To evaluate the efficacy of ablative laser use for skin resurfacing and adverse events as a consequence of treatment in comparison to other modalities, a PRISMA‐compliant systematic review (Systematic Review Registration Number: 204016) of twelve electronic databases was conducted for the terms “ablative laser” and “skin resurfacing” from March 2002 until July 2020. Studies included meta‐analyses, randomized control trials, cohort studies, and case reports to facilitate evaluation of the data. All articles were evaluated for bias. The search strategy produced 34 studies. Of 1093 patients included in the studies of interest, adverse events were reported in a total of 106 patients (9.7%). Higher rates of adverse events were described in nonablative therapies (12.2% ± 2.19%, 31 events) when compared with ablative therapy (8.28% ± 2.46%, 81 events). 147 patients (13.4%) reported no side effects, 68 (6.22%) reported expected, transient self‐resolving events, and five (0.046%) presented with hypertrophic scarring. Excluding transient events, ablative lasers had fewer complications overall when compared with nonablative lasers (2.56% ± 2.19% vs 7.48% ± 3.29%). This systematic review suggests ablative laser use for skin resurfacing is a safe and effective modality to treat a range of pathologies from photodamage and acne scars to hidradenitis suppurativa and posttraumatic scarring from basal cell carcinoma excision. Further studies are needed, but these results suggest that ablative lasers are a superior, safe, and effective modality to treat damaged skin.     

Genetic alterations in RAS‐regulated pathway in acral lentiginous melanoma

Studies integrating clinicopathological and genetic features have revealed distinct patterns of genomic aberrations in Melanoma. Distributions of BRAF or NRAS mutations and gains of several oncogenes differ among melanoma subgroups, while 9p21 deletions are found in all melanoma subtypes. In the study, status of genes involved in cell cycle progression and apoptosis was evaluated in a panel of 17 frozen primary acral melanomas. NRAS mutations were found in 17% of the tumors. In contrast, BRAF mutations were not found. Gains of AURKA gene (20q13.3) were detected in 37.5% of samples, gains of CCND1 gene (11q13) or TERT gene (5p15.33) in 31.2% and gains of NRAS gene (1p13.2) in 25%. Alterations in 9p21 were identified in 69% of tumors. Gains of 11q13 and 20q13 were mutually exclusive, and 1p13.2 gain was associated with 5p15.33. Our findings showed that alterations in RAS‐related pathways are present in 87.5% of acral lentiginous melanomas.     

Self‐resolving superficial primary cutaneous mucormycosis in a 7‐week‐old infant

A 7‐week‐old girl, born at 30 weeks' gestational age, presented to clinic for evaluation of a crop of vesicular lesions that were noted after removal of a bandage that had been in place for 4 days. A punch biopsy of the lesion revealed fungal elements that were later identified as Rhizopus spp. The lesion began to self‐resolve, and no further treatment was needed, with full resolution of the lesion by 1 month after presentation. Clinicians should be aware of the variable presentations of mucormycosis and consider fungal infection in the differential diagnosis when evaluating vulnerable patients with skin eruptions.     

Multiple New-Onset Subcutaneous Nodules of the Upper Extremity Digits: Giant Cell Tumor of Tendon Sheath and Lipoma

A black woman with the concurrent onset of two subcutaneous nodules located on the digits of her upper extremities is described. Initially, a single systemic disorder was considered; yet, the lesions differed in morphology and consistency. Microscopic examination of the nodules showed a giant cell tumor of tendon sheath and a lipoma. Although Occam's “razor” suggests that multiple lesions in the same person are more likely to represent variable manifestations of a single disorder than several different diseases in that individual, the simultaneously appearing lesions in this patient represented two different conditions.